Healthcare and pharmaceuticals team - two new appointments

We’re now NatWest Group

Come and visit us for all our latest news, insights and everything NatWest Group.

Healthcare and pharmaceuticals team - two new appointments

Royal Bank of Scotland Corporate & Institutional Banking (RBS CIB) is growing its market-leading healthcare and pharmaceuticals team with the appointments of Emily Makinson and Paul Weeks as associate director and director respectively.

Our news

07 January 2013

The appointments are part of RBS CIB’s drive to enhance the range of services it offers to clients in the healthcare sector. Makinson and Weeks will work to build the team’s proposition into the fast-growing medical technology (‘medtech’) and pharmaceutical industries, whilst also continuing to focus on corporates in the private care and hospital spaces.

Makinson moves to her new position from RBS’s Structured Finance Corporates team where she played a lead role in the recent financings for Abbey Total Care Group and of Grant Thornton UK LLP. Prior to this she has spent time in RBS’s Markets and International Banking (M and IB) Loan Market Origination team, having joined Royal Bank of Scotland in 2008 on its Corporate Banking Graduate Programme.

Weeks joins the healthcare and pharmaceuticals team from RBS’s Global Restructuring Group. As corporate relationship director, his role was to pursue turnaround opportunities for financially distressed corporates, focusing on operational and balance sheet restructures. Paul started his career as a graduate trainee at RBS Insurance and has since worked as strategy manager for RBS Major Corporate Banking and assistant director for RBS Property Structured Finance.

Based at the bank’s Bishopsgate offices in London, RBS CIB’s healthcare and pharmaceuticals team works with a wide range of organisations from care homes and dental practices to suppliers of medical devices. It helps them with a variety of financing requirements including the provision of world-class day-to-day operational banking through to funding growth via acquisition and capital expansion.

"I am absolutely delighted to be joining the healthcare and pharmaceuticals team. It is a fast growing and dynamic part of RBS and, capitalising on the team’s already strong presence in the market, we have exciting expansion plans for the division. I look forward to working with my new colleagues and clients to grow the business."

Paul Weeks

"The healthcare and pharmaceuticals team already has an impressive track record, counting Nuffield Hospitals and the Priory Group among its clients. This is an exciting time for the division, and our expansion of the business into the pharmaceutical and medtech sectors further underlines our commitment to companies within the healthcare industry."

Emily Makinson

Posted In

Our news


Latest news

RBS to help 2.5 million people each year to be more financially capable

RBS has today committed to helping 2.5 million people in the UK each year to improve their financial capability.

RBS to increase lending to sustainable energy sector following £1.1bn securitisation of loans to UK sustainable energy market

RBS has executed a £1.1bn securitisation deal with Macquarie Infrastructure Debt Investment Solutions (MIDIS), which will allow the bank to recycle capital and increase lending to the sustainable or renewable energy sectors.

RBS launches £1 billion Female Entrepreneurship Funding and announces targets to help create at least 50k new businesses by 2023

RBS has today announced a new £1 billion in funding through NatWest to support female entrepreneurs in the UK to scale and grow – the largest intervention by a UK lender focused specifically on female-led businesses.

We’re now NatWest Group

Come and visit us for all our latest news, insights and everything NatWest Group.

Set Tab for lightbox